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Erdheim-Chester disease (ECD) is a rare, systemic,
noneLangerhans cell histiocytosis (non-LCH).
Diagnosis is based on a combination of specific
radiologic, histologic, and clinical findings. Although
there have been hundreds of prior reports of ECD,
very few cases have described the spectrum of
potential cutaneous manifestations.1-4 Most of these
cases describe ECD skin findings as xanthelasmalike
lesions surrounding the periorbital area,1,2 whereas 2
patients were reported to have a red-brown papular
eruption affecting the chest and lower extremities.3,4
We discuss a case of a 45-year-old woman with an
extensive childhood history of LCH who then
presented more than 20 years later with a new
eruption of polymorphous skin lesions distributed
over the face, trunk, arms, and legs. These lesions
were clinically varied yet histologically all consistent
with xanthogranulomas. Upon further workup, the
patient was found to have specific radiographic
findings pathognomonic for ECD and a BRAF
V600E mutation, which has been reported in both
LCH and ECD. Our case is unique, in that this patient
was affected by both diseases within her lifetime.
Identification of the BRAF V600E mutation suggests
the possibility of a common origin between LCH and
ECD.
CASE REPORT
A 45-year-old woman presented with complaints
of a new widespread eruption across her face, arms,
and legs. The patient described an occasionally
pruritic, nonpainful, papular rash that would eruptts of Dermatology,a Internal Medicine,b and
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059. E-mail: michael.girardi@yale.edu.sporadically without a known trigger and resolve to
leave hyperpigmented macules. A review of systems
was noncontributory, including no episodes of fever,
chills, night sweats, or weight loss. The patient’s
medical history was significant for childhood LCH
that manifested as eosinophilic granuloma of the
cranium, treated at age 3 with surgery, radiation, and
vincristine. She also had recurrent disease treated
with prednisone and methotrexate between the ages
of 9 and 24. The patient had no other chronicmedical
problems, no allergies, and no relevant family history
and was not taking any medications. On physical
examination, erythema was noted on her face, arms,
chest, and back. Upon closer inspection, the ery-
thema was composed of numerous, pinpoint, pink-
to-red papules (Fig 1). In addition, examination
found yellow papules coalescing into thin plaques
along her bilateral temples and periorbital regions
(Fig 1) and scattered 2- to 4-mm red brown papules
across her arms and legs. Biopsies performed on the
arm, leg, and face, found foamy cells and multinu-
cleated cells in the dermis without 2-toned cyto-
plasm. Immunohistochemistry found positive CD68
and negative CD1a and S-100 staining, consistent
with non-LCH histiocytosis (Fig 2). The patient was
subsequently referred to the hematology departmentJAAD Case Reports 2016;2:128-31.
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Fig 1. Clinical photographs of ECD.
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malignancy given the xanthogranulomas on histol-
ogy, but findings from a thorough workup (a com-
plete blood count, comprehensive metabolic panel,
lactate dehydrogenase, peripheral blood flow cy-
tometry, serum protein electrophoresis, serum im-
munofixation electrophoresis, b-2 microglobulin,
quantitative immunoglobulins, and serum free light
chains) were normal. A positron emission tomogra-
phyecomputerized tomography (PET-CT) scan was
performed to evaluate for multiorgan involvement.The PET-CT scan was significant for multifocal 18F
flurodeoxyglucose avid sclerotic changes in the
sternum, sacrum, and bilateral symmetric uptake in
the femoral and tibial bones, and the diagnosis of
ECD was made based on these pathognomonic
radiologic findings (Fig 3). Given recent findings of
the high prevalence of BRAF V600E mutation in ECD
patients and potential therapeutic implications,5,6
the tissue was tested for this mutation and found to
be BRAF V600E positive. The patient was then
enrolled in an open-label, phase II clinical trial
Fig 3. Characteristic radiographic findings of ECD from PET-CT. A, CT image shows bilateral
osteosclerotic changes of the femur and tibia. B, PET image with FDG uptake in the bilateral
femur and tibia.
Fig 2. Histology photographs of ECD. (A, Hematoxylin-eosin stain; original magnification:
320. B, CD1a stain; original magnification 320. C, S-100 stain; original magnification: 320.)
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mutationepositive cancers, but her participation
was discontinued because of the development of
severe myalgias and arthralgias during the trial.
DISCUSSION
ECD is a rare, non-LCH, neoplasm that is diag-
nosed by clinical, histologic, and radiologic findings.
Previously reported cases of ECD have a slight male
predominance, disease onset typically in the fifth to
seventh decades of life1 and bone pain as the most
common presenting symptom.2-4,7 Patients with ECD
have pathognomonic changes of bilateral symmetric
sclerosis of the diametaphyseal regions of the long
bones on plain radiographs and symmetric techne-
tium Tc 99m labeling of the distal long bones with
bone scintigraphy.1-4,7 Biopsies (taken typically from
bone) show foamy histiocytes without any Birbeck
granules with immunohistochemistry positive for
CD68 and negative for CD1a and S-100.3,4,7
Although our patient did have the characteristic
histologic and radiologic findings that established the
diagnosis of ECD, the initial cutaneous manifestations
ofECDweredifferent from thosepreviouslydescribed
in the literature. Although ECD has been reported to
significantly affect the cardiovascular, pulmonary,
renal, and central nervous systems,3,7 involvement of
the skin is relatively uncommon, with approximately
28%of reportedcaseshavingany skinmanifestations.1
The most commonly described dermatologic findings
in ECD include xanthomalike papules and periorbital
xanthelasmalike skin lesions.2,8 Other reports
describe red-brown papular lesions affecting the
extremities and trunk.9,10 Our reported patient with
ECD manifested a diverse array of cutaneous mani-
festations, all with identical histologic findings.
Although there is no standardized treatment for
ECD, a recent consensus guideline for the diagnosis
and treatment of ECD reported interferon-alfa as first-
line therapy with the largest amount of supporting
evidence.1,7,11,12 Treatment with interferon-alfa was
identified as an individual predictor of survival of
ECD patients.1 Another treatment currently being
investigated is the use of vemurafenib in ECD
patients with a BRAF V600E mutation.6 Recent
studies have shown a high prevalence of the BRAF
V600E mutation in up to 54% to 100% of tested ECD
patients and 38% to 68%of LCHpatients.5 In addition,
no such mutation has been found in any of the other
tested histiocytoses, including Rosai-Dorfman dis-
ease, juvenile xanthogranuloma, histiocytic sarcoma,
xanthoma disseminatum, interdigitating dendritic
cell sarcoma, and necrobiotic xanthogranuloma,which suggests a common origin between ECD and
LCH.5 Vemurafenib is a serine/threonine kinase
inhibitor that inhibits the RAS-ERK cellular signaling
pathway, which is constitutively activated by the
BRAF V600E mutation.6 Although marked response
of ECD to vemurafenib has been reported in several
cases, the drug is still being studied to determine the
safety, optimal duration of therapy, and potential
adverse drug reactions.6 Treatment continues to pose
a challenge, as there is no standardized regimen or
any modality that has demonstrated disease eradica-
tion. However, the discovery of the highly prevalent
BRAF V600E is a promising treatment target.
Early diagnosis of ECD could potentially limit
disease morbidity and mortality by initiating early
treatment. Our case is unique to previously reported
cases of ECD, as our patient presented initially with a
clinical array of cutaneous lesions and pathogno-
monic radiographic findings. Her history of childhood
LCH raises a question of whether there is a common
origin linking the 2 histiocytoses, ECD and LCH.
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